Trump Administration Announces 2026 National Drug Control Strategy — Includes Proposal to Classify Psychoactive Hemp Derivatives like Delta‑8 THC and HHC as Schedule I

The Trump administration's 2026 National Drug Control Strategy includes provisions to designate psychoactive hemp derivatives — including Delta‑8 THC and HHC — as Schedule I substances, a move that is reverberating through the hemp industry.

For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.